Adults Vaccines Market Strategic Outlook, Emerging Technologies, and Forecast Opportunities 2032

The adult vaccines market covers immunization products designed to prevent infectious diseases in individuals aged 18 and above. These vaccines protect against conditions such as influenza, pneumococcal disease, shingles, hepatitis, HPV, meningococcal infections, and COVID-19. Market growth is driven by increasing awareness of preventive healthcare, rising prevalence of infectious diseases, expanding adult immunization programs, and government initiatives promoting vaccination coverage. Aging populations, especially in developed countries, are boosting demand as older adults are more vulnerable to infections. North America currently dominates the market due to strong healthcare infrastructure, high vaccination rates, and supportive policies, while Asia-Pacific is expected to see rapid growth with rising healthcare spending and awareness. Key challenges include vaccine hesitancy, unequal access in low- and middle-income countries, and high costs of some newer vaccines.

The global adult vaccines market size was valued at USD 40.70 billion in 2024 and is projected to grow from USD 42.06 billion in 2025 to USD 83.78 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period. North America dominated the adult vaccines market with a 45.52% share in 2024, driven by strong immunization programs, rising awareness of preventable diseases, and growing government and private sector initiatives to improve vaccination coverage.

Top Companies in the Market

• Bavarian Nordic (Denmark)

• GSK plc (U.K.)

• EMERGENT (U.S.)

• Merck & Co., Inc. (U.S.)

• Inovio Pharmaceuticals, Inc. (U.S.)

• Pifzer Inc. (U.S.)

• Sanofi (France)

• CSL (Australia)

• AstraZeneca (U.K.)

Key Industry Development

June 2025: Merck initiated the MOBILIZE-1 Phase 3 clinical trial to evaluate the efficacy, safety, and immunogenicity of V181, a single-dose dengue vaccine candidate for adults aged 18 years and above.

Market Drivers & Restraints

Drivers

• The rising incidence of infectious diseases among adults, coupled with an expanding geriatric population whose immune resilience declines with age.

• Awareness of adult immunization benefits and preventive health practices.

• Favorable regulatory frameworks and robust healthcare infrastructure, particularly in regions like North America.

Restraints

• High costs of vaccine development, clinical trials, and the need for cold-chain logistics, which can limit access in lower-income regions.

• Insufficient healthcare infrastructure and limited public awareness in developing regions, inhibiting vaccination uptake.

Market Competitive Landscape

The global adults vaccines market exhibits moderate concentration, with several major players commanding significant shares:

• GSK plc holds a substantial market share, thanks to a strong portfolio that includes adult-targeted vaccines such as Shingrix, along with collaborative agreements with partners to develop advanced vaccines.

• Sanofi also commands a notable share, driven by its broad global presence, extensive vaccine lineup, and active pipeline.

• Merck & Co., Inc. is recognized among leading competitors in the adults vaccines space.

Market Segments & Report Scope

The adults vaccines market is analyzed and forecast across multiple dimensions:

• By Type: Recombinant/Conjugate/Subunit; Inactivated; mRNA; Viral Vector; Live Attenuated; Toxoid; Others.

• By Route of Administration: Parenteral; Oral.

• By Disease Indication: Various infectious diseases commonly affecting adults are addressed under this segment.

• By Region: Includes North America, Asia Pacific, Latin America, Middle East & Africa, and others with country-level and subregion analysis.

• Study Period: Historical (2019–2023), Base Year 2024, Estimated Year 2025, Forecast Period 2025–2032.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/adults-vaccines-market-113663 

Regional Insights

North America leads the global adults vaccines market, representing 45.52% of the total market share in 2024 (USD 18.53 billion). The region benefits from high patient populations affected by viral and bacterial infections, advanced healthcare infrastructure, favorable regulations, and strong uptake of vaccination.

Asia Pacific is the fastest-growing market region. Demand for preventive adult vaccination is surging due to high incidence of infectious diseases, bolstered by intensified R&D activities and government immunization initiatives.

Future Market Scope & Forecast

Over the forecast period (2025–2032), the global adults vaccines market is expected to nearly double in value—to USD 83.78 billion—propelled by persistent disease burden among adults, aging demographics, and expanding vaccine innovation technologies such as mRNA, viral vectors, and recombinant vaccines.

With recombinant/conjugate/subunit vaccines already dominating by type, emerging platforms such as mRNA offer potential for further market disruption and growth as pipeline candidates become available.

Regional expansion will likely continue, with North America maintaining dominance and Asia Pacific accelerating adoption—supported by public health mandates, awareness campaigns, and infrastructure investments.

Additionally, continued investments in clinical trials—such as Merck’s MOBILIZE-1 dengue vaccine study—highlight the sector’s dynamic R&D pipeline and potential for new adult-specific immunization breakthroughs.

Conclusion

The adults vaccines market stands at a pivotal juncture in 2025—valued at USD 42.06 billion—and is on track to reach USD 83.78 billion by 2032. Key factors underpinning this growth include epidemiological pressures, demographic shifts, and technological innovation, all underpinned by strong contributions from major industry players such as GSK, Sanofi, and Merck. North America remains the current powerhouse, while Asia Pacific charts the future’s fastest growth. With an expanding portfolio of vaccine types and evolving platforms like mRNA, the adult immunization space is set to redefine preventive healthcare on a global scale.

About Us:Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com